PT  - JOURNAL ARTICLE
AU  - Koski, Jessica R.
AU  - Langohr, Laura
AU  - Räisänen, Tuulia
AU  - Lahtinen, Atte K.
AU  - Hakkarainen, Marja
AU  - Heckman, Caroline A.
AU  - Wartiovaara-Kautto, Ulla
AU  - Pitkänen, Esa
AU  - Kilpivaara, Outi
TI  - Pathogenicity evaluation of coding germline variants identifies rare alleles enriched in hematological patients of a founder population
AID  - 10.1101/2024.10.23.24315723
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.10.23.24315723
4099  - http://medrxiv.org/content/early/2024/10/23/2024.10.23.24315723.short
4100  - http://medrxiv.org/content/early/2024/10/23/2024.10.23.24315723.full
AB  - Background The clinical significance of most germline variants in hematological malignancies (HMs) remains unknown. This presents a challenge in the clinical setting, as the inability to accurately detect pathogenic variants can influence therapeutic decisions. Population isolates have been shown to be beneficial in pathogenic variant discovery due to presence of rare deleterious variants in relatively high frequencies.Methods We developed and applied PaVaDi, a computational pipeline that follows American College of Medical Genetics and Genomics (ACMG) guidelines, to evaluate the pathogenicity of germline variants in 511 HM patients from the Finnish founder population. We conducted an exome-wide burden analysis to assess the overall contribution of pathogenic variants to HMs and identified significant gene associations. We also examined genes previously associated with hematological diseases and DNA repair in more detail, and performed protein stability analyses to resolve variants of unknown significance (VUS).Results The exome-wide burden analysis revealed potential pathogenic alleles in CUX2, RNPC3, and MFSD2A that have not previously been linked to HM predisposition. We also identified the largest series of CHEK2 variant carriers reported in hematological diseases, including pathogenic/likely pathogenic (P/LP) variants (n=19), Ile200Thr (i.e., Ile157Thr) (n=49), and other variants of uncertain significance (n=3). CHEK2 variants were 1.7-fold enriched in patients compared to controls (13.9% vs 8.3%, p=2×10−5). Strikingly, Ile200Thr was enriched over four-fold in acute lymphoblastic leukemia patients. Finally, protein structure stability analyses suggested novel MPO variants to be potentially highly deleterious.Conclusions This study highlights the importance of germline testing in hematological malignancies and demonstrates the utility of population isolates for pathogenic variant discovery. Our findings identify a significant burden of deleterious variants in HM patients, particularly in CHEK2, and underscore the potential of multi-disease joint analyses in revealing germline contributions to hematological diseases.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Research Council of Finland (322675, 349760), Sigrid Jusélius Foundation, the Finnish Special Governmental Subsidy for Health Sciences, Research, and Training, the Helsinki University Hospital Comprehensive Cancer Research Funding, Cancer Foundation Finland, and iCAN Digital Precision Cancer Medicine Flagship.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Helsinki University Hospital gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll unidentifiable data is available within the article and its supporting files. The individual-level sequencing data cannot be made publicly available because the research participant consent does not include authorization to share identifiable data.ACMGAmerican College of Medical Genetics and GenomicsAMLAcute myeloid leukemiaALLacute lymphoid leukemiaBBenignBMBone marrowBMFBone marrow failureCDACongenital dyserythropoietic anemiaCMLChronic myeloid leukemiaCVIcommon variable immunodeficiencyDDRDNA damage response and repairFDRFalse-discovery rateHISTHistiocytosis syndromeHMHematological malignancyIMMAutoimmune cytopenia and/or autoimmune lymphoproliferative syndromeHSCTHematopoietic stem cell transplantationLBLikely benignLOHLoss-of-heterozygosityLPLikely pathogenicLPChronic lymphoproliferative diseaseMb WaldenströmWaldenström’s macroglobulinemiaMDSMyelodysplastic syndromeMMMultiple myelomaMPAMixed phenotype acute leukemiaMPNMyeloproliferative neoplasmOROdds ratioPPathogenicVUSvariant of unknown significance